D‐dimer testing in clinical practice in the era of COVID‐19

D‐dimer is a fragment of crosslinked fibrin resulting from plasmin cleavage of fibrin clots and hence an indirect biomarker of the hemostatic system activation. Early in the coronavirus disease 2019 (COVID‐19) pandemic, several studies described coagulation disorders in affected patients, including...

Full description

Saved in:
Bibliographic Details
Published in:Research and practice in thrombosis and haemostasis 2022-05, Vol.6 (4), p.e12730-n/a, Article e12730
Main Authors: Auditeau, Claire, Khider, Lina, Planquette, Benjamin, Sanchez, Olivier, Smadja, David M., Gendron, Nicolas
Format: Article
Language:English
Subjects:
Algorithms
anticoagulant
biomarker
Biomarkers
Clinical medicine
Coronaviruses
COVID-19 vaccines
COVID‐19
Disease
disseminated intravascular coagulation
D‐dimer
fibrin
fibrin fragment D
fibrinogen degradation products
Forum
Hospitalization
Pandemics
predictive value of tests
prognosis
pulmonary embolism
Pulmonary embolisms
Thromboembolism
Thrombosis
Tomography
Ultrasonic imaging
Veins & arteries
venous thromboembolism
Womens health
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:D‐dimer is a fragment of crosslinked fibrin resulting from plasmin cleavage of fibrin clots and hence an indirect biomarker of the hemostatic system activation. Early in the coronavirus disease 2019 (COVID‐19) pandemic, several studies described coagulation disorders in affected patients, including high D‐dimer levels. Consequently, D‐dimer has been widely used in not‐yet‐approved indications. Ruling out pulmonary embolism and deep vein thrombosis in patients with low or intermediate clinical suspicion is the main application of D‐dimer. D‐dimer is also used to estimate the risk of venous thromboembolism recurrence and is included in the ISTH algorithm for the diagnosis of disseminated intravascular coagulation. Finally, numerous studies identified high D‐dimer levels as a biomarker of poor prognosis in hospitalized patients with COVID‐19. This report focuses on validated applications of D‐dimer testing in patients with and without COVID‐19.
ISSN:2475-0379
2475-0379
DOI:10.1002/rth2.12730